Innovative Molecules
Latest round
- Series A
Last raised
- May 2021
Total raised
- $24M
Investors
- 1
About Innovative Molecules
Founded in 2016, Innovative Molecules GmbH specializes in creating therapeutics for HSV infections. The company has not undergone significant strategic pivots since its inception. Thomas Hoffmann, the founder, has been instrumental in steering the company's research and development efforts.Innovative Molecules specializes in the development of advanced therapeutics targeting herpes simplex virus (HSV) infections. Its flagship product, IM-250, is an orally available, selective HSV-helicase primase inhibitor that inhibits DNA unwinding, crucial for viral replication.The revenue structure of Innovative Molecules is primarily based on the sales of its flagship product, IM-250, within a B2B framework targeting healthcare providers and pharmaceutical distributors. The product is expected to be acquired in bulk by healthcare institutions, establishing a direct revenue channel. The company is focused on developing new therapeutics for HSV and aims to expand its market reach into additional European regions following successful regulatory approvals. Ongoing innovations and product advancements are expected to support these growth initiatives.
Who invested in Innovative Molecules
1 investor across 1 round
See all investors in Innovative Molecules
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
May 28, 2021
Amount
$24M
Investors
Questions about Innovative Molecules
Who invested in Innovative Molecules?
Innovative Molecules has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Innovative Molecules raised?
Innovative Molecules has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Innovative Molecules last raise money?
Innovative Molecules's most recent round on record is a Series A, in May 2021.
What does Innovative Molecules do?
Founded in 2016, Innovative Molecules GmbH specializes in creating therapeutics for HSV infections.
Where is Innovative Molecules headquartered?
Innovative Molecules is headquartered in Munich, Germany.
Which VCs invest in companies like Innovative Molecules?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Innovative Molecules's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Innovative Molecules? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.